Danish pharmaceutical giant Novo Nordisk gains significant access with the approval of its weight-loss drug Wegovy in China. This move grants Novo Nordisk entry into the world's second-largest economy, targeting a growing population facing obesity challenges.
Key Considerations:
Wegovy targets patients with a Body Mass Index (BMI) of 30 or higher alongside...
